Pooled results from the 14 datasets on 12 case-control studies showed that MTR A2756G polymorphism was not associated with CHD susceptibility under the allele model (OR: 0.96, 95% CI: 0.86 to 1.07, P = 0.43, I2 = 4%; Fig 2A), heterozygote model (OR: 0.95, 95% CI: 0.84 to 1.07, P = 0.41, I2 = 0%; Fig 2B), homozygote model (OR: 1.00, 95% CI: 0.64 to 1.55, P = 0.99, I2 = 17%; Fig 2C), dominant genetic model (OR: 0.95, 95% CI: 0.84 to 1.07, P = 0.41, I2 = 0%; Fig 2D), or recessive genetic model (OR: 0.94, 95% CI: 0.62 to 1.43, P = 0.32, I2 = 13%; Fig 2E). Here, MTR is linked to coronary artery disorder.